Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...

Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...

Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...